PortViewPortView
Nuvation Bio logo

Nuvation Bio (NUVB-WT) Stock Analysis

NYSEHealthcareBiotechnology

$0.07-0.86%
1-year price historyRange $0.03 – $0.09
52-week range$0.07
$0.01$0.14

What Nuvation Bio does

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for oncology. The company's pipeline includes small molecule drug candidates aimed at treating various types of cancer. Its strategy involves acquiring and developing novel therapeutic candidates to address significant unmet medical needs in cancer treatment.

Key metrics

Market cap
$23.00M
P/E (TTM)
0.00
EPS (TTM)
$0.00
Beta
2.05
Dividend yield
0.00%
Revenue / share
$0.49
50-day avg
$0.20
200-day avg
$0.20
52-week high
$0.14
52-week low
$0.01
CEO
David Hung

ETFs linked to NUVB-WT

Broad-market and Healthcare sector ETFs an investor holding Nuvation Bio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NUVB-WT fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze NUVB-WT in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Nuvation Bio?
Nuvation Bio trades under the ticker NUVB-WT on NYSE.
Which exchange is NUVB-WT listed on?
NUVB-WT is listed on NYSE.
What sector does Nuvation Bio operate in?
Nuvation Bio is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze NUVB-WT in a portfolio?
PortView shows NUVB-WT's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.